Maintenance. We are currently updating the site. Please check back shortly

Thomson Reuters Foundation

Inform - Connect - Empower

Glaxo recalls hypertension drug made at Novartis plant

Source: Thomson Reuters Foundation - Fri, 24 Feb 2012 23:35 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

Feb 24 (Reuters) - GlaxoSmithKline has recalled 394,230 bottles of its DynaCirc CR hypertension drug from the U.S. market after the manufacturer, Novartis, reported inconsistent packaging practices.

The generic drug is manufactured at a Novartis plant in Lincoln, Nebraska.

Glaxo said in a statement that it has received no reports of adverse events nor any complaints of contamination or tablet mix-ups in batches of the drug, but decided on the recall as a precautionary measure.

The London-based company said it does not known when the Novartis facility will resume operations. Novartis said last month it had temporarily closed the plant to accelerate improvements at the site.

Glaxo spokesman Kevin Colgan said alternative treatments are available to patients currently being treated with DynaCirc.

(Reporting By Deena Beasley; Editing by Bernard Orr)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus